WO2024104650A1 - Formulation de lavage anti-acné - Google Patents

Formulation de lavage anti-acné Download PDF

Info

Publication number
WO2024104650A1
WO2024104650A1 PCT/EP2023/077961 EP2023077961W WO2024104650A1 WO 2024104650 A1 WO2024104650 A1 WO 2024104650A1 EP 2023077961 W EP2023077961 W EP 2023077961W WO 2024104650 A1 WO2024104650 A1 WO 2024104650A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
preparation according
polylysine
malassezia
skin
Prior art date
Application number
PCT/EP2023/077961
Other languages
German (de)
English (en)
Inventor
Philipp Rübenhaus
Benjamin TRILLER
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Publication of WO2024104650A1 publication Critical patent/WO2024104650A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/45—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/88—Polyamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations

Definitions

  • the invention belongs to the cosmetic and pharmaceutical field and relates to a washing formulation for the treatment of acne and fungal acne.
  • Acne in the narrower sense acne vulgaris refers to various diseases of the sebaceous gland follicles, which are characterized by secretion and keratinization disorders, subsequent inflammation and possible scarring.
  • Acne vulgaris occurs mainly during puberty and is usually concentrated on areas of the skin with a large number of sebaceous glands (face, neck, chest, back). Sebaceous gland hyperplasia and keratinization disorders of the follicles lead to their blockage, with the formation of comedones and the efflorescences typical of acne vulgaris (Pschyrembel, Clinical Dictionary, 258th edition, Walter de Gruyter-Verlag, Berlin, 1998).
  • effective active ingredients are needed that reduce or prevent the colonization of the skin with microorganisms such as Propionibacterium acnes. The active ingredients therefore not only contribute to an improved skin condition but also to an improved well-being of the user.
  • Pityrosporum Folliculitis also known as Malassezia (Pityrosporum) folliculitis is an acne-like outbreak on the human skin that is often accompanied by itching and occurs most frequently in areas with a lot of sebum activity. This includes primarily the face (especially forehead), neck, shoulders, chest and back.
  • Malassezia folliculitis is often referred to colloquially as fungal acne, even though this skin disease is not acne per se.
  • the colloquial name is simply based on similar symptoms.
  • Malassezia folliculitis is a fungal infection that is often misdiagnosed as a bacterial form of acne. This can be extremely frustrating for the sufferer, as the misdiagnosis often leads to unnecessary and prolonged treatment with medications such as antibiotics, which only make the condition worse.
  • Another problem is the fact that a large number of patients experience a mixed form of bacterial acne and Malassezia folliculitis.
  • the disadvantage is that there are currently few or no known combinations of active ingredients that effectively reduce bacterial acne and Malassezia folliculitis.
  • Malassezia is a genus of yeast or fungi that is a common part of the skin's micro and mycobiome (i.e. the healthy bacteria and yeasts that live on the skin) and is found in an estimated 92% of all people, but for reasons not yet fully understood, it becomes pathogenic in selected individuals and causes Malassezia folliculitis.
  • Malassezia folliculitis is caused by the Malassezia yeasts penetrating deeper into the skin glands. This is usually accompanied by increased sebum production. As a result, skin irritations such as small pimples, redness and itching occur.
  • Various species of Malassezia yeast are known. These are M. caprae, M. cuniculi, M.
  • M. equine M. furfur
  • M. globosa M. japonica
  • M. nana M. obtuse
  • M. pachydermatis M. restricta
  • M. slooffiae M. sympodialis.
  • Malassezia folliculitis is mostly caused by M. globosa and/or M. furfur.
  • a number of patients who do not want or cannot tolerate oral antifungal treatment try treating Malassezia folliculitis topically with an antifungal shampoo.
  • the shampoo is usually easy to apply because you can drip it onto your chest, back, or shoulders after applying it to your neck or scalp.
  • ketoconazole The most commonly used active ingredient is ketoconazole. Studies have shown that ketoconazole inhibits every species of Malassezia yeast, with significantly better efficacy than other antifungals. For example, it has a lower minimum inhibitory concentration (MIC) against Malassezia than zinc pyrithione, selenium sulfide, clotrimazole and bifonazole.
  • MIC minimum inhibitory concentration
  • ketoconazole cream or take 100 mg of oral itraconazole twice daily.
  • the 37 patients who used ketoconazole cream showed an average improvement after 27 to 43 days.
  • the 7 patients who used oral itraconazole showed improvement after 14 to 18 days. Consequently, topical application does not show rapid improvement. (105)
  • ketoconazole has limited effectiveness against Malassezia folliculitis.
  • climbazole benzoyl peroxide
  • salicylic acid and zinc phyritine are also known to be used in the topical treatment of Malassezia folliculitis.
  • the disadvantage is that the active ingredients alone are often not effective enough to reduce Malassezia yeasts when applied topically to the skin, especially the facial skin. As a result, Malassezia folliculitis is not adequately combated and there is no improvement in the appearance of the skin.
  • active ingredients such as benzoyl peroxide have the disadvantage that, after application to the skin, they can cause bleaching of textiles that come into contact with the skin.
  • a first subject matter of the present invention is a cosmetic or dermatological cleansing preparation comprising a) coco-betaine, and b) one or more substances selected from the group sodium laureth-6 carboxylate, capryloyl/caproyl methyl glucamide and sodium lauroyl sarcosinate.
  • a preferred subject of the invention is a cosmetic or dermatological cleansing preparation comprising a) coco-betaine, and b) sodium laureth-6 carboxylate.
  • a preferred subject of the invention is a cosmetic or dermatological cleansing preparation comprising a) Coco-Betaine, and b) Capryloyl/Caproyl Methyl Glucamide.
  • a preferred subject of the invention is a cosmetic or dermatological cleansing preparation comprising a) Coco-Betaine, and b) Sodium Lauroyl Sarcosinate.
  • Another object of the invention is the cosmetic use of the preparation according to the invention for reducing Propionibacterium acnes and/or Malassezia furfur on human skin.
  • Another object of the invention is the preparation according to the invention for use in the treatment of acne and/or Malassezia folliculitis on human skin.
  • the invention can also be used particularly effectively in the treatment of conventional acne.
  • a combination product has been made available that can be used against both acne and Pityrosporum Folliculitis.
  • the problem of misdiagnosis no longer exists, so that the consumer or patient notices an improvement in their skin in every case.
  • a particularly effective reduction in Propionibacterium acnes and/or Malassezia Furfur could be achieved even with a particularly short exposure time of around 5 minutes on human skin. The preparation is washed off with water after the exposure time.
  • the active ingredient combination acts synergistically on acne and/or Malassezia folliculitis, each with respect to the reduction of Propionibacterium acnes and/or Malassezia furfur.
  • normal conditions refers to 20 ° C, 1013 hPa and a relative humidity of 50%.
  • skin refers exclusively to human skin.
  • Propionibacterium acnes When the term “against Propionibacterium acnes” is used in this disclosure, it means that Propionibacterium acnes is killed and/or the growth and/or spread of the bacterium is reduced and/or prevented.
  • the term “against Malassezia furfur” means that Malassezia furfur is killed and/or the growth and/or spread of Malassezia furfur is reduced and/or prevented. If percentages by weight (wt. %) are given below without reference to a particular composition or specific mixture, these details always refer to the total weight of the preparation. If ratios of components/substances/groups of substances are disclosed below, these ratios refer to weight ratios of the components/substances/groups of substances mentioned.
  • weight percentage ranges for the components of the preparation are given below, the disclosure of the present application also includes all individual values in steps of 0.1 wt.% within these weight percentage ranges.
  • Emulsifiers are all substances listed under the name “emulsifying agent” in the International Cosmetic Ingredient Dictionary and Handbook, Thirteenth Edition 2010, (ISBN 1-882621-47-6).
  • Surfactants are all substances listed under the name “surfactant” in the International Cosmetic Ingredient Dictionary and Handbook, Thirteenth Edition 2010, (ISBN 1-882621-47-6).
  • viscosity values refer to a measurement at 25°C in a 150 ml wide-neck bottle (VWR No.: 807-0001) using the Rheomat R 123 from proRheo.
  • the Rheomat R 123 from proRheo GmbH is a rotational viscometer, i.e. a measuring body rotates in the substance to be measured. The force required to rotate the measuring body in the sample at a specified speed is measured. The viscosity is calculated from this torque, the speed of the measuring body and the geometric dimensions of the measuring system used.
  • the measuring body used is measuring body No. 1 (item no. 200 0191), suitable for a viscosity range up to 10,000 [mPa-s], speed range 62.5 min-1.
  • this average always refers to arithmetic means.
  • coco-betaine is contained in a proportion of 0.1 to 10 wt.%, preferably 1.2 to 8 wt.% and particularly preferably 2.8 to 5.5 wt.%, in each case based on the total weight of the preparation.
  • the preparation comprises sodium laureth-6 carboxylate
  • the weight ratio of sodium laureth-6 carboxylate to cocobetaine is from 10:1 to 1:10, preferably from 5:1 to 1:5, preferably from 2:1 to 1:2, preferably from 1.5:1 to 1:1.5 and particularly preferably from 1.2:1 to 1:1.2.
  • the preparation comprises capryloyl/caproyl methyl glucamide
  • the weight ratio of capryloyl/caproyl methyl glucamide to cocobetaine is from 10:1 to 1:10, preferably from 5:1 to 1:5, preferably from 2:1 to 1:2, preferably from 1.5:1 to 1:1.5 and particularly preferably from 1.2:1 to 1:1.2.
  • the preparation comprises sodium lauroyl sarcosinate
  • the weight ratio of sodium lauroyl sarcosinate to cocobetaine is from 10:1 to 1:10, preferably from 5:1 to 1:5, preferably from 2:1 to 1:2, preferably from 1.5:1 to 1:1.5 and particularly preferably from 1.2:1 to 1:1.2.
  • the preparation comprises sodium laureth-6 carboxylate, capryloyl/caproyl methyl glucamide and/or sodium lauroyl sarcosinate
  • the weight ratio of the total amount of sodium laureth-6 carboxylate, capryloyl/caproyl methyl glucamide and sodium lauroyl sarcosinate to cocobetaine is from 10:1 to 1:10, preferably from 5:1 to 1:5, preferably from 2:1 to 1:2, preferably from 1.5:1 to 1:1.5 and particularly preferably from 1.2:1 to 1:1.2.
  • sodium laureth-6 carboxylate is contained in a proportion of 0.1 to 10 wt. %, preferably 1.2 to 8 wt. % and particularly preferably 2.8 to 5.5 wt. % based in each case on the total weight of the preparation.
  • capryloyl/caproyl methyl glucamide is contained in a proportion of 0.1 to 10 wt.%, preferably 1.2 to 8 wt.% and particularly preferably 2.8 to 5.5 wt.%, in each case based on the total weight of the preparation.
  • sodium lauroyl sarcosinate is contained in a proportion of 0.1 to 10 wt.%, preferably 1.2 to 8 wt.% and particularly preferably 2.8 to 5.5 wt.%, in each case based on the total weight of the preparation.
  • sodium laureth-6 carboxylate, capryloyl/caproyl methyl glucamide and/or sodium lauroyl sarcosinate are contained in a proportion of 0.1 to 10 wt. %, preferably 1.2 to 8 wt. % and particularly preferably 2.8 to 5.5 wt. %, in each case based on the total weight of the preparation.
  • polylysines are homopolymers of the amino acid lysine.
  • the precursor amino acid lysine contains two amino groups, one on the a-carbon and one on the £-carbon. Both can be the site of polymerization, resulting in a-polylysine or e-polylysine.
  • Polylysine is a homopolypeptide from the group of cationic polymers: polylysine contains a positively charged hydrophilic amino group at pH 7.
  • the proportion of polylysine is from 0.01 to 1 wt.%, preferably from 0.1 to 0.5 wt.% and particularly preferably from 0.15 to 0.3 wt.%, in each case based on the preparation according to the invention.
  • the proportion of e-polylysine is from 0.01 to 1 wt.%, preferably from 0.1 to 0.5 wt.% and particularly preferably from 0.15 to 0.3 wt.%, in each case based on the preparation according to the invention.
  • Sodium benzoate is an additive of this type typically used in cleaning preparations. Consequently, it is preferred if sodium benzoate is included, and it is further preferred if the total content of sodium benzoate is from 0.1 to 0.8% by weight, based on the total weight of the preparation.
  • glycerin is included. If glycerin is included, it is preferred if the proportion of glycerin is from 0.5 to 6% by weight, preferably from 1.5 to 4% by weight, based on the total weight of the preparation.
  • the pH value of the preparation is from 4.0 to 5.0, preferably from 4.2 to 4.8.
  • the pH value is preferably adjusted by adding citric acid or sodium hydroxide.
  • the preparation comprises water as a cosmetic carrier, wherein the proportion of water is advantageously from 50 to 98 wt.%, preferably from 60 to 90 wt.%, based on the total weight of the preparation.
  • dyes are included in the preparation. These allow the appearance of the preparation to be individually adapted.
  • the preparations of the invention have a viscosity of at least 2000 mPa s. In this way, they can be stored in and applied from a tube with a small outlet or in a dispenser or pump foamer.
  • preparations according to the invention can comprise further additives and active ingredients, provided that these are not incompatible with the preparations according to the invention.
  • All example recipes have a pH value of 4.5.
  • Example 4 Example 7 and Example 11 to Example 16 are in accordance with the invention.
  • the table above also shows the results for an untreated control for the suspension tests (column: control).
  • the formulations according to the invention show a surprising reduction of c.acnes and/or m.furfur in the suspension test. Other surfactant combinations were not able to bring about a reduction in CFUs.
  • Stock cultures in glycerine which were created according to European standard 12353, are stored in the refrigerator at 5°C.
  • the first passage is prepared from this liquid stock culture.
  • the culture is spread onto appropriate agar plates using a sterile disposable inoculation loop (see Table 1 Culture conditions). This culture is incubated (see Table Culture conditions).
  • a second passage is prepared by picking up a few colonies with a sterile inoculation loop and then spreading them on another, new agar plate. This second passage is then incubated for 24 hours at the appropriate temperature (see table of culture conditions).
  • the second passage obtained can be used for the suspension test.
  • the culture suspensions are prepared as follows:
  • C. acnes 2-3 colonies from the first passage are taken and placed in a CELLSTAR CELLreactor tube filled with anaerobic medium. This tube is vortexed and incubated for at least 18 hours at 37°C in an anaerobic box with anaerobic pads. The OD is also set to a value of around 0.2 ( ⁇ 0.01). Anaerobic medium is used for this.
  • 50%/500pL of the preparation to be tested is diluted with 300pL water and 100pL 3g/L BSA is added to sterilized Eppendorf reaction vessels.
  • 800pL water and 100pL 3g/L BSA are added.
  • the individual components are always determined in duplicate.
  • 1:10 dilutions are made with neutralization medium of all samples after 60 seconds and 300 seconds (900pL neutralization medium + 100pL test sample). From this dilution, a 1:1 000 dilution is prepared (990pL neutralization medium + 10pL 1:10 dilution).
  • the diluted samples are plated on agar plates using a spiral platter (see Table 1 Culture conditions). After the test is completed, all agar plates are stored in the incubator for incubation and evaluated on the Countermat after incubation (see Table 1 Culture conditions). The results in CFll are given in the tables with the examples.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne un agent imperméabilisant pour le platelage.
PCT/EP2023/077961 2022-11-15 2023-10-10 Formulation de lavage anti-acné WO2024104650A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102022212093.0A DE102022212093A1 (de) 2022-11-15 2022-11-15 Waschformulierung gegen Akne
DE102022212093.0 2022-11-15

Publications (1)

Publication Number Publication Date
WO2024104650A1 true WO2024104650A1 (fr) 2024-05-23

Family

ID=88297012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/077961 WO2024104650A1 (fr) 2022-11-15 2023-10-10 Formulation de lavage anti-acné

Country Status (2)

Country Link
DE (1) DE102022212093A1 (fr)
WO (1) WO2024104650A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011600A1 (fr) * 2015-07-13 2017-01-19 Dr. Reddy's Laboratories, Ltd. Compositions de rétinoïdes pour la voie topique
US20190365619A1 (en) * 2018-05-31 2019-12-05 L'oreal Anti-dandruff cleansing composition
WO2022147226A1 (fr) * 2020-12-31 2022-07-07 Melaleuca, Inc. Produit de douche/shampooing pour bébé

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011600A1 (fr) * 2015-07-13 2017-01-19 Dr. Reddy's Laboratories, Ltd. Compositions de rétinoïdes pour la voie topique
US20190365619A1 (en) * 2018-05-31 2019-12-05 L'oreal Anti-dandruff cleansing composition
WO2022147226A1 (fr) * 2020-12-31 2022-07-07 Melaleuca, Inc. Produit de douche/shampooing pour bébé

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"International Cosmetic Ingredient Dictionary and Handbook", 2010
DATABASE GNPD [online] MINTEL; 12 March 2021 (2021-03-12), ANONYMOUS: "Inner Cleanser", XP093117132, retrieved from https://www.gnpd.com/sinatra/recordpage/8553947/ Database accession no. 8553947 *
DATABASE GNPD [online] MINTEL; 22 February 2022 (2022-02-22), ANONYMOUS: "Face Wash Gel", XP093117140, retrieved from https://www.gnpd.com/sinatra/recordpage/9398984/ Database accession no. 9398984 *
DATABASE GNPD [online] MINTEL; 31 August 2022 (2022-08-31), ANONYMOUS: "Acne Gentle Wash", XP093117143, retrieved from https://www.gnpd.com/sinatra/recordpage/9860546/ Database accession no. 9860546 *
PSCHYREMBEL: "Klinisches Wörterbuch", vol. 258, 1998, WALTER DE GRUYTER-VERLAG
W. UMBACHKOSMETIKENTWICKLUNG: "Herstellung und Anwendung kosmetischer Mittel", 1995, THIEME VERLAG

Also Published As

Publication number Publication date
DE102022212093A1 (de) 2024-05-16

Similar Documents

Publication Publication Date Title
DE69626971T2 (de) Schnell und anhaltend wirkendes topisches antispetikum
KR101420599B1 (ko) 항여드름제를 함유하는 조성물 및 이의 용도
DE69713904T2 (de) Kosmetische, dermopharmazeutische oder tierärztliche zusammensetzungen zur antiseptischen behandlung von menschlicher oder tierischer haut
DE69527765T2 (de) Verwendung von Hyaluronsäure oder sein Salz zur Behandlung von Hauterkrankungen
CN107789308A (zh) 一种温和控油祛痘精华
DE69819443T2 (de) Antimikrobielle mittel zur topische verwendung
DE60012610T2 (de) Selektive antibakterielle Zusammensetzunge
EP3806820A1 (fr) Préparation cosmétique contre l'acné
WO2018087766A1 (fr) Compositions topiques destinées au traitement de l'acné
DE202017105515U1 (de) Zusammensetzung, insbesondere zur Pflege des Intim- oder Vaginalbereichs
DE60113167T2 (de) Verwendung von Verbindungen, mit denen die physikalisch-chemischen Eigenschaften der Haut und/oder der Schleimhäute verändert werden können, als Wirkstoffe, die das Anhaften von Mikroorganismen verhindern oder vermindern
EP2549976B1 (fr) Association de principes actifs respectueuse de la peau pour lutter contre l'acné
DE60212842T2 (de) Dermatologische zusammensetzungen, die nikotinsäure oder nikotinsäureamid und sphingoid-base enthalten
WO2024104650A1 (fr) Formulation de lavage anti-acné
EP1955591A1 (fr) Produit de soin et traitement antimicrobien de la peau
EP2386309B1 (fr) Bulbine frutescens gel
DE10347824B4 (de) Pharmazeutische oder kosmetische Zusammensetzung zur Behandlung der Haut
EP2542211B1 (fr) Émulsion huile dans l'eau antimicrobienne contenant des composés ammonium quaternaires
EP3236920B1 (fr) Préparation antimicrobienne comprenant des alcanes de bispyridinium, des éthers de 1- ou 2-(c1 à c24-alkyl)-glycérol et des alcane-1,2-diols
JP2000212057A (ja) 化粧料組成物
RU2286135C1 (ru) Крем для век
DE102021201638A1 (de) Wirkstoffkombination
DE69709317T2 (de) Antiseptische zusammensetzungen auf basis von chlorobutanol und chlorhexidin
DE202023102783U1 (de) Zusammensetzung einer antibakteriellen Lotion mit Zitronengrasöl, angereichert mit Bioaktivstoffen
CN118593392A (zh) 一种男士清洁抗菌湿巾

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23786263

Country of ref document: EP

Kind code of ref document: A1